CD274 and non-small cell lung carcinoma: Martin Reck is a chief physician at the Lung Clinic Grosshansdorf, Germany, and principal investigator in KEYNOTE-024 (NCT02142738) (Reck et al., 2016; Brahmer et al., 2017; Reck et al., 2021), a phase 3 study for PD-L1-positive NSCLC, which compared pembrolizumab with platinum-based doublet chemotherapy.